Medtronic PLC $MDT Shares Acquired by Cresset Asset Management LLC

Cresset Asset Management LLC lifted its holdings in shares of Medtronic PLC (NYSE:MDT) by 7.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,411 shares of the medical technology company’s stock after purchasing an additional 12,538 shares during the period. Cresset Asset Management LLC’s holdings in Medtronic were worth $18,363,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Delos Wealth Advisors LLC purchased a new position in Medtronic during the second quarter worth $27,000. Corundum Trust Company INC purchased a new stake in shares of Medtronic in the third quarter valued at $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the third quarter valued at $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic during the 3rd quarter worth about $33,000. Finally, Tripletail Wealth Management LLC acquired a new position in Medtronic in the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Royal Bank Of Canada raised their target price on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Barclays reissued an “overweight” rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday, February 18th. Finally, Morgan Stanley lifted their price objective on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $110.74.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Stock Performance

Shares of NYSE:MDT opened at $95.58 on Thursday. The business has a 50-day moving average of $98.89 and a two-hundred day moving average of $96.98. The firm has a market capitalization of $122.71 billion, a PE ratio of 26.62, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).